Skip to main content
. Author manuscript; available in PMC: 2015 Oct 7.
Published in final edited form as: Leuk Lymphoma. 2013 Jan 30;54(9):1915–1920. doi: 10.3109/10428194.2013.763397

Table III.

Response

Best Response Frequency Percent [95% CI]
OR 14 47 [28–66]
 CR 8 27 [12–46
 PR 6 20 [8–39
SD 10 33 [17–53
PD 3 10 [2–27]
Not evaluable for response* 3 10 [2–27]
*

Patients not evaluable for response came off study prior to restaging for reasons other than clinical progression

CR=complete response; OR=overall response; PD=progressive disease; PR=partial response; SD=stable disease